Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T86918
|
||||
| Former ID |
TTDS00397
|
||||
| Target Name |
Pancreatic alpha-amylase
|
||||
| Gene Name |
AMY2A
|
||||
| Synonyms |
1,4-alpha-D-glucan glucanohydrolase; PA; AMY2A
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Cystic fibrosis [ICD9: 277; ICD10: E84] | ||||
| Pancreatic disease [ICD10: K85-K86] | |||||
| BioChemical Class |
Glycosylases
|
||||
| UniProt ID | |||||
| EC Number |
EC 3.2.1.1
|
||||
| Sequence |
MKFFLLLFTIGFCWAQYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPP
NENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGN AVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGL LDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAG SKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWG FVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWP RQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQP FTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGI KIYVSDDGKAHFSISNSAEDPFIAIHAESKL |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Pancrecarb | Drug Info | NDA filed | Pancreatic disease | [1] |
| Liprotamase | Drug Info | Phase 3 | Cystic fibrosis | [2] | |
| Inhibitor | 4,6-Dideoxy-4-Amino-Alpha-D-Glucose | Drug Info | [3] | ||
| 5-Hydroxymethyl-Chonduritol | Drug Info | [3] | |||
| 6-Deoxy-Alpha-D-Glucose | Drug Info | [3] | |||
| Acarbose Derived Hexasaccharide | Drug Info | [3] | |||
| Acarviostatin III03 | Drug Info | [4] | |||
| Acarviostatin IV03 | Drug Info | [4] | |||
| Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen | Drug Info | [5] | |||
| Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen | Drug Info | [5] | |||
| Beta-D-Glucose | Drug Info | [3] | |||
| Hydroxycitric acid | Drug Info | [6] | |||
| Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam | Drug Info | [7] | |||
| Pyroglutamic Acid | Drug Info | [3] | |||
| Modulator | Liprotamase | Drug Info | [8] | ||
| Pancrecarb | Drug Info | [1] | |||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Digestive Care. | ||||
| REF 2 | ClinicalTrials.gov (NCT00500084) Phase III ALTU-135 CP Safety Trial. U.S. National Institutes of Health. | ||||
| REF 3 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 4 | Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of alpha-amylase. Carbohydr Res. 2008 Apr 7;343(5):882-92. Epub 2008 Jan 26. | ||||
| REF 5 | Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30. Epub 2008 Jun 14. | ||||
| REF 6 | Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol. 2007 Jul;75(5):977-82. Epub 2007 May 3. | ||||
| REF 7 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-4. Nucleic Acids Res. 2011 January | ||||
| REF 8 | Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.